Fabenol® Max, a standardised aqueous extract from Phaseolus vulgaris L., and ‘reduces the absorption of carbohydrates’: evaluation of a health claim pursuant toArticle 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)
Research output: Contribution to journal › Journal article › Commissioned › peer-review
Standard
Fabenol® Max, a standardised aqueous extract from Phaseolus vulgaris L., and ‘reduces the absorption of carbohydrates’: evaluation of a health claim pursuant toArticle 13(5) of Regulation (EC) No 1924/2006 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).
In: E F S A Journal, Vol. 14, No. 2, 4401, 23.02.2016.Research output: Contribution to journal › Journal article › Commissioned › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Fabenol® Max, a standardised aqueous extract from Phaseolus vulgaris L., and ‘reduces the absorption of carbohydrates’: evaluation of a health claim pursuant toArticle 13(5) of Regulation (EC) No 1924/2006
T2 - (Scientific Opinion)
AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
AU - Sjödin, Anders Mikael
N1 - EFSA 2016 4401
PY - 2016/2/23
Y1 - 2016/2/23
N2 - Following an application from Ecopharma BVBA, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Fabenol® Max and ‘reduces the absorption of carbohydrates’. The Panel considers that Fabenol® Max, which is an aqueous extract from Phaseolus vulgaris L. standardised by its content of α-amylase inhibitor, is sufficiently characterised. According to the applicant, consumption of the food ‘offers potential benefits in the maintenance of healthy blood sugar levels’. The meaning of ‘healthy blood sugar levels’ was not specified. The target population proposed by the applicant is ‘the general population that wants to manage their carbohydrate intake (for the maintenance of healthy blood sugar levels or optimal body composition)’. The Panel notesthat the claimed effect was not sufficiently defined and that the applicant did not provide any further information. The Panel concludes that a cause and effect relationship cannot be established between the consumption of Fabenol® Max and a beneficial physiological effect.
AB - Following an application from Ecopharma BVBA, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to Fabenol® Max and ‘reduces the absorption of carbohydrates’. The Panel considers that Fabenol® Max, which is an aqueous extract from Phaseolus vulgaris L. standardised by its content of α-amylase inhibitor, is sufficiently characterised. According to the applicant, consumption of the food ‘offers potential benefits in the maintenance of healthy blood sugar levels’. The meaning of ‘healthy blood sugar levels’ was not specified. The target population proposed by the applicant is ‘the general population that wants to manage their carbohydrate intake (for the maintenance of healthy blood sugar levels or optimal body composition)’. The Panel notesthat the claimed effect was not sufficiently defined and that the applicant did not provide any further information. The Panel concludes that a cause and effect relationship cannot be established between the consumption of Fabenol® Max and a beneficial physiological effect.
KW - Faculty of Science
KW - Fabenol® Max
KW - Kidney bean extract
KW - Carbohydrate absorption
KW - Health claims
U2 - 10.2903/j.efsa.2016.4401
DO - 10.2903/j.efsa.2016.4401
M3 - Journal article
VL - 14
JO - E F S A Journal
JF - E F S A Journal
SN - 1831-4732
IS - 2
M1 - 4401
ER -
ID: 187629710